SCHEMBL6345585

SCHEMBL6345585

COc1ccc([C@@]2(O)CCCC[C@H]2NS(=O)(=O)C(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.43
SLC6A3 Q01959 5/20 0.43
CNR2 P34972 1/20 0.40
SLC6A9 P48067 4/20 0.39
OPRM1 P35372 4/20 0.39
SLC6A5 Q9Y345 2/20 0.39
OPRL1 P41146 1/20 0.39
SLC22A1 O15245 3/20 0.38
SLC6A2 P23975 3/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
TSHR P16473 1/20 0.37
POLB P06746 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6244911 1.00 SLC6A4 (0.43) SLC6A4SLC6A3CNR2SLC6A9OPRM1
SCHEMBL6357784 1.00 SLC6A4 (0.43) SLC6A4SLC6A3CNR2SLC6A9OPRM1
SCHEMBL6347708 0.87 LMNA (0.41) CNR2SLC6A9OPRM1SLC6A5OPRL1
SCHEMBL6347705 0.87 LMNA (0.41) CNR2SLC6A9OPRM1SLC6A5OPRL1
SCHEMBL6356541 0.87 LMNA (0.41) CNR2SLC6A9OPRM1SLC6A5OPRL1
SCHEMBL6348747 0.86 GRIA4 (0.36) SLC6A4OPRM1SLC6A2OPRD1OPRK1
SCHEMBL6344008 0.85 TRPA1 (0.40) SLC6A4SLC6A3SLC6A9OPRM1SLC6A5
SCHEMBL6353145 0.85 GRIA4 (0.45) CNR2SLC6A9OPRM1SLC6A5OPRL1
SCHEMBL6353143 0.85 GRIA4 (0.45) CNR2SLC6A9OPRM1SLC6A5OPRL1
SCHEMBL6356775 0.85 ALDH1A1 (0.36) L3MBTL1ALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 SLC6A4 74/4885SLC6A3 73/4885CNR2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.